The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.1

MIGRAINE PREVENTION — Patients with frequent or severe migraine headaches and those who cannot take or do not have an adequate response to acute treatment are candidates for preventive treatment.2,3

Beta blockers and the antiepileptic drugs valproate (Depakote, and others) and topiramate (Topamax, and generics) are commonly used for ... more      

Would you like to read the rest of this issue?  Gain access below.